Skip to main content

Table 2 Yearly vaccination status according to age group and type of pneumococcal vaccine received during 2010 ~ 2015

From: The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia

  Pneumococcal pneumonia cases by year
2010 (n = 179) 2011 (n = 329) 2012 (n = 273) 2013 (n = 81) 2014 (n = 82) 2015 (n = 39) Total (n = 983)
Cases with any pneumococcal vaccination according to age 45 (25.1) 125 (38.0) 114 (41.8) 45 (55.6) 66 (80.5) 26 (66.7) 421/983 (42.8)
 < 2 years 5/26 (19.2) 9/33 (27.3) 9/23 (39.1) 3/9 (33.3) 13/18 (72.2) 3/3 (100) 42/112 (37.5)
 2-5 years 27/78 (34.6) 78/152 (51.3) 55/90 (61.1) 26/30 (86.7) 39/44 (88.6) 15/16 (93.8) 240/410 (65.9)
 5-18 years 13/75 (17.3) 38/144 (26.3) 50/160 (31.3) 16/42 (38.1) 14/20 (70.0) 8/20 (40.0) 139/461 (30.2)
Type of pneumococcal vaccine received
 PCV7 43/45 (95.6) 116/125 (92.8) 104/114 (91.2) 32/45 (71.1) 21/66 (31.8) 0/26 (0.0) 316/983 (32.2)
 PCV10 0 (0.0) 3/125 (2.4) 2/114 (1.75) 3/45 (6.7) 4/66 (6.1) 3/26 (11.5) 15/983 (1.5)
 PCV13 1/45 (2.2) 2/125 (1.6) 15/114 (13.2) 22/45 (48.9) 54/66 (81.8) 26/26 (100.0) 120/983 (12.2)
 PPV23 1/45 (2.22) 5/125 (4.0) 1/114 (0.9) 0/45 (0.0) 1/66 (1.5) 0/26 (0.0) 8/983 (0.8)
  1. Data are shown as n/N (%)
  2. PCV7, 7-valent polysaccharide conjugate vaccine; PCV10, 10-valent polysaccharide conjugate vaccine; PCV13, 13-valent polysaccharide conjugate vaccine; PPV23, 23-valent polysaccharide pneumococcal vaccine